Market News

Redfin (RDFN) Reaches $21.75 After 4.00% Down Move; Last Week KemPharm, Inc. (KMPH) Analysts

The stock of Redfin Corporation (NASDAQ:RDFN) is a huge mover today! The stock decreased 5.48% or $1.261 during the last trading session, reaching $21.749. About 1.08 million shares traded or 60.43% up from the average. Redfin Corporation (NASDAQ:RDFN) has 0.00% since January 29, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 9 months negative chart setup for the $1.77 billion company. It was reported on Jan, 29 by Barchart.com. We have $20.88 PT which if reached, will make NASDAQ:RDFN worth $70.84 million less.

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm had 15 analyst reports since August 14, 2015 according to SRatingsIntel. On Wednesday, June 28 the stock rating was maintained by Oppenheimer with “Buy”. The firm has “Buy” rating given on Thursday, August 10 by Oppenheimer. Roth Capital maintained KemPharm, Inc. (NASDAQ:KMPH) on Friday, August 11 with “Buy” rating. The company was maintained on Tuesday, January 16 by RBC Capital Markets. Canaccord Genuity reinitiated the shares of KMPH in report on Tuesday, December 20 with “Buy” rating. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, May 6 report. The stock of KemPharm, Inc. (NASDAQ:KMPH) has “Buy” rating given on Monday, September 11 by Canaccord Genuity. The stock of KemPharm, Inc. (NASDAQ:KMPH) earned “Buy” rating by Canaccord Genuity on Thursday, August 10. The firm has “Buy” rating by Roth Capital given on Wednesday, June 28. The stock of KemPharm, Inc. (NASDAQ:KMPH) has “Outperform” rating given on Friday, August 14 by RBC Capital Markets. See KemPharm, Inc. (NASDAQ:KMPH) latest ratings:

16/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $9.0 Maintain
11/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $7.0 Maintain
11/08/2017 Broker: Roth Capital Rating: Buy New Target: $8.0000 Maintain
10/08/2017 Broker: Oppenheimer Rating: Buy New Target: $13.0000 Maintain
10/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $7.0000 Maintain

Among 6 analysts covering Redfin (NASDAQ:RDFN), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. Redfin had 8 analyst reports since August 22, 2017 according to SRatingsIntel. The firm has “Neutral” rating by Bank of America given on Friday, November 10. The rating was maintained by Oppenheimer with “Outperform” on Friday, November 10.

Analysts await Redfin Corporation (NASDAQ:RDFN) to report earnings on February, 8. After $0.12 actual earnings per share reported by Redfin Corporation for the previous quarter, Wall Street now forecasts -141.67% negative EPS growth.

Redfin Corporation operates as a real estate brokerage firm in the United States. The company has market cap of $1.77 billion. The firm operates an online real estate marketplace and provides real estate services, such as assisting individuals to purchase or sell their residential property. It currently has negative earnings. It also provides title and settlement services; and originate mortgages.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The company has market cap of $85.03 million. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. It currently has negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

The stock increased 0.89% or $0.051 during the last trading session, reaching $5.801. About 51,463 shares traded or 9.47% up from the average. KemPharm, Inc. (NASDAQ:KMPH) has declined 32.16% since January 29, 2017 and is downtrending. It has underperformed by 48.86% the S&P500.

Leave a Reply

Your email address will not be published. Required fields are marked *